14. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including G-CSF, GM-CSF or recombinant erythropoetin) within 4 weeks prior to the first dose of study treatment. Note: Patients receiving stable dose of growth factors with a haemoglobin value that meets Inclusion Criterion 9b may be included.